Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval

As antecedently reported, TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with an $8 price target aft Cardamyst nasal spray was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus bushed successful adults. The statement is cleanable with nary market-limiting warnings oregon monitoring requirements, notes the analyst, who besides points retired that Cardamyst volition beryllium disposable successful retail pharmacies successful Q1 of 2026 with a wholesale acquisition outgo of $1,649.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level information and almighty investing tools designed to assistance you marque smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation truthful your portfolio is ever positioned for maximum potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected MIST:

Disclaimer & DisclosureReport an Issue

• Milestone Pharmaceuticals upgraded to Buy from Hold astatine TD Cowen

• Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential

• Milestone Pharmaceuticals terms people raised to $8 from $5 astatine H.C. Wainwright

• Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST

• Milestone Pharmaceuticals receives FDA support of CARDAMYST